NCT00073736View on ClinicalTrials.gov

Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

July 31, 2007

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

MB07133 300mg/m2/day

7-day continuous infusion in 28-day cycles

DRUG

MB07133 600 mg/m2/day

7-day continuous infusion in 28-day cycles

DRUG

MB07133 1200 mg/m2/day

7-day continuous infusion in 28-day cycles

DRUG

MB07133 1800 mg/m2/day

7-day continuous infusion in 28-day cycles

DRUG

MB07133 2400 mg/m2/day

7-day continuous infusion in 28-day cycles

Trial Locations (4)

114

Tri-Services General Hospital, Taipei

333

Chang-Gung Memorial Hospital, Taipei

92868

University of California at Irvine, Orange

Unknown

Prince of Wales Hospital - Comprehensive Cancer Trial Unit, Shatin, New Territories

Sponsors
All Listed Sponsors
lead

Ligand Pharmaceuticals

INDUSTRY

NCT00073736 - Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter